רווח לפני ריבית, מסים ופחת: Axsome Therapeutics, Inc. (AXSM)

Axsome Therapeutics (AXSM) maintains a high standing in neurotherapy, providing treatments for depression and migraines funded by insurance payouts. Operating cash flow before depreciation on GURU.Markets demonstrates the current trend, where the 0.00 mark reflects the latest data. Revenue growth is supported by active sales of new proprietary drugs, creating strong momentum for business development.

The commercial expansion of Auvelity and Sunosi directly determines the cash flow volume that the EBITDA_Co metric captures through operating profit before depreciation and interest. This metric allows investors to assess the actual ability of Axsome Therapeutics (AXSM) to generate cash for pipeline development, excluding the impact of debt load and accounting write-offs when analyzing the fundamental stability of the business.